子宫内膜癌患者血清泛素耦联酶2C、三基序蛋白27表达水平及其与病理参数的相关性

doi:10.3969/j.issn.1006-5725.2024.13.008

Abstract

Abstract:

Objective To investigate the expression level of serum ubiquitin-conjugating enzyme 2C （UBE2C） and tripartite motif-containing protein 27 （TRIM27） in patients with endometrial cancer （EC） and their correlation with pathological parameters. Methods A total of 96 EC patients from March 2020 to March 2023 were selected as EC group； 65 patients with endometrial atypical hyperplasia （EAH） as EAH group， and 80 healthy subjects as the control group. Enzyme linked immunosorbent assay was applied to analyze the expression level of serum UBE2C and TRIM27. The relationship between serum UBE2C， TRIM27， and pathological data was analyzed； receiver operating characteristic was applied to evaluate the predictive value of serum UBE2C and TRIM27 level for EC. Results The level of serum UBE2C and TRIM27 of EC patients was obviously higher than that in healthy subjects （P < 0.05）， and was correlated with tumor diameter， tumor differentiation， lymph node metastasis， FIGO stage， muscle layer invasion depth， cervical involvement， estrogen receptor expression， and progestogen receptor expression （P < 0.05）. There was positive correlation between serum UBE2C and TRIM27 （r = 0.475， P < 0.001）； and the level of serum UBE2C and TRIM27 was positively correlated with tumor diameter， lymph node metastasis， FIGO stage， and depth of musclular invasion， but negatively with tumor differentiation， estrogen receptor expression， and progestogen receptor expression （P < 0.05）. The combination of UBE2C and TRIM27 had obviously higher AUC in evaluating EC than single detection （Z_{UBE2C-combination}=3.406， P < 0.001， Z_{TRIM27-combination} = 3.285， P = 0.001）. Conclusion The expression level of UBE2C and TRIM27 in serum of EC patients is up-regulated， which is closely related to pathological parameters. The level of serum UBE2C and TRIM27 can provide reference for early diagnosis of EC.

Key words: endometrial cancer, ubiquitin-conjugating enzyme 2C, tripartite motif-containing protein 27, pathological parameters, correlation

CLC Number:

R737.33

Fei CHAI,Zhenwen CHEN,Hongyan LIU,Su LI,Yuanyuan GONG,Yingying. ZHAO. Expression level of serum UBE2C and TRIM27 in patients with endometrial cancer and their correlation with pathological parameters[J]. The Journal of Practical Medicine, 2024, 40(13): 1808-1813.

Figures/Tables 6

Tab.1

Tab.2

Tab.3

Tab.4

Tab.5

Fig.1

References 23

1	MAKKER V， MACKAY H， RAY-COQUARD I， et al. Endometrial cancer［J］. Nat Rev Dis Primers， 2021， 7（1）：1-44. doi:10.1038/s41572-021-00324-8 doi: 10.1038/s41572-021-00324-8
2	COLL-DE LA RUBIA E， MARTINEZ-GARCIA E， DITTMAR G， et al. Prognostic Biomarkers in Endometrial Cancer： A Systematic Review and Meta-Analysis［J］. J Clin Med， 2020， 9（6）：1-20. doi:10.3390/jcm9061900 doi: 10.3390/jcm9061900
3	YUAN L， YANG Z， ZHAO J， et al. Pan-Cancer Bioinformatics Analysis of Gene UBE2C［J］. Front Genet， 2022， 13（1）：1-11. doi:10.3389/fgene.2022.893358 doi: 10.3389/fgene.2022.893358
4	LIN S， QIU L， LIANG K， et al. KAT2A/E2F1 Promotes Cell Proliferation and Migration via Upregulating the Expression of UBE2C in Pan-Cancer［J］. Genes （Basel）， 2022， 13（10）：1-21. doi:10.3390/genes13101817 doi: 10.3390/genes13101817
5	LIU S， TIAN Y， ZHENG Y， et al. TRIM27 acts as an oncogene and regulates cell proliferation and metastasis in non-small cell lung cancer through SIX3-β-catenin signaling［J］. Aging （Albany NY）， 2020， 12（24）：25564-25580. doi:10.18632/aging.104163 doi: 10.18632/aging.104163
6	USSAKLI C， USUBUTUN A， DINCER N， et al. Serous versus high-grade endometrioid endometrial carcinoma： immunohistochemistry of RFP is not useful for differentiation）［J］. Pol J Pathol， 2016，67（3）：221-227. doi:10.5114/pjp.2016.63773 doi: 10.5114/pjp.2016.63773
7	周琦，吴小华，刘继红，等.子宫内膜癌诊断与治疗指南（第四版）［J］.中国实用妇科与产科杂志， 2018， 34（8）：880-886.
8	中华医学会病理学分会女性生殖疾病学组.子宫内膜癌病理诊断规范［J］.中华病理学杂志， 2020， 49（3）：214-219. doi:10.3760/cma.j.issn.0529-5807.2020.03.002 doi: 10.3760/cma.j.issn.0529-5807.2020.03.002
9	MARIN-JIMENEZ J A， GARCIA-MULERO S， MATIAS-GUIU X， et al. Facts and Hopes in Immunotherapy of Endometrial Cancer［J］. Clin Cancer Res， 2022， 28（22）：4849-4860. doi:10.1158/1078-0432.ccr-21-1564 doi: 10.1158/1078-0432.ccr-21-1564
10	COADA C A， DONDI G， RAVEGNINIi G， et al. Classification Systems of Endometrial Cancer： A Comparative Study about Old and New［J］. Diagnostics （Basel）， 2021， 12（1）：1-15. doi:10.3390/diagnostics12010033 doi: 10.3390/diagnostics12010033
11	YEN T T， WANG T L， ADER A N， et al. Molecular Classification and Emerging Targeted Therapy in Endometrial Cancer［J］. Int J Gynecol Pathol， 2020， 39（1）：26-35. doi:10.1097/pgp.0000000000000585 doi: 10.1097/pgp.0000000000000585
12	张瑜，张静，王乐，等.血清人附睾蛋白4及糖类抗原125对判断子宫内膜癌淋巴结转移的临床意义［J］.实用医学杂志， 2020， 36（10）：1340-1348. doi:10.3969/j.issn.1006-5725.2020.10.014 doi: 10.3969/j.issn.1006-5725.2020.10.014
13	NJOKU K， BARR C E， CROSBIE E J. Current and Emerging Prognostic Biomarkers in Endometrial Cancer［J］. Front Oncol， 2022， 12（1）：1-16. doi:10.3389/fonc.2022.890908 doi: 10.3389/fonc.2022.890908
14	BROOKS R A， FLEMING G F， LASTRA R R， et al. Current recommendations and recent progress in endometrial cancer［J］. CA Cancer J Clin， 2019， 69（4）：258-279. doi:10.3322/caac.21561 doi: 10.3322/caac.21561
15	LU Z N， SONG J， SUN T H， et al. UBE2C affects breast cancer proliferation through the AKT/mTOR signaling pathway［J］. Chin Med J （Engl）， 2021， 134（20）：2465-2474. doi:10.1097/cm9.0000000000001708 doi: 10.1097/cm9.0000000000001708
16	LIU Y， ZHAO R， CHI S， et al. UBE2C Is Upregulated by Estrogen and Promotes Epithelial-Mesenchymal Transition via p53 in Endometrial Cancer［J］. Mol Cancer Res， 2020， 18（2）：204-215. doi:10.1158/1541-7786.mcr-19-0561 doi: 10.1158/1541-7786.mcr-19-0561
17	DASTSOOZ H， CEREDA M， DONNA D， et al. A Comprehensive Bioinformatics Analysis of UBE2C in Cancers［J］. Int J Mol Sci， 2019， 20（9）：1-19. doi:10.3390/ijms20092228 doi: 10.3390/ijms20092228
18	ZHANG Y， LI X， GONG Y， et al. Aberrant expression of UBE2C in endometrial cancer and its correlation to epithelial mesenchymal transition［J］. Medicine （Baltimore）， 2023， 102（20）：1-6. doi:10.1097/md.0000000000033834 doi: 10.1097/md.0000000000033834
19	ZHAO R， LIU Y， WANG Z， et al. UBE2C-mediated Autophagy Inhibition via Ubiquitination of SIRT1 Contributes to Endometrial Cancer Progression［J］. Mol Cancer Res， 2023， 21（6）：564-577. doi:10.1158/1541-7786.mcr-22-0825 doi: 10.1158/1541-7786.mcr-22-0825
20	YU C， RAO D， WANG T， et al. Emerging roles of TRIM27 in cancer and other human diseases［J］. Front Cell Dev Biol， 2022， 10（1）：1-10. doi:10.3389/fcell.2022.1004429 doi: 10.3389/fcell.2022.1004429
21	YU H， WAN L， TANG Z， et al. TRIM27 regulates the expression of PDCD4 by the ubiquitin‑proteasome pathway in ovarian and endometrial cancer cells［J］. Oncol Rep， 2022， 48（1）：1-11. doi:10.3892/or.2022.8331 doi: 10.3892/or.2022.8331
22	LI Y， MENG Q， WANG L， et al. TRIM27 protects against cardiac ischemia-reperfusion injury by suppression of apoptosis and inflammation via negatively regulating p53［J］. Biochem Biophys Res Commun， 2021， 557（1）：127-134. doi:10.1016/j.bbrc.2021.03.061 doi: 10.1016/j.bbrc.2021.03.061
23	王蒙. 术前IMP3、RFP检测在子宫内膜癌诊断中的应用［J］. 山东医药， 2018， 58（1）：84-86. doi:10.3969/j.issn.1002-266X.2018.01.028 doi: 10.3969/j.issn.1002-266X.2018.01.028

一般资料	EC组（n = 96）	EAH组（n = 65）	对照组（n = 80）	χ ² 值	P值
年龄
> 50岁（n = 115）	50（52.08）	35（53.85）	30（37.50）	5.060	0.080
≤ 50岁（n = 126）	46（47.92）	30（46.15）	50（62.50）	5.060	0.080
体质量指数
> 23 kg/m²（n = 117）	52（54.17）	33（50.77）	32（40.00）	3.682	0.159
≤ 23 kg/m²（n = 124）	44（45.83）	32（49.23）	48（60.00）	3.682	0.159
绝经状态
是（n = 125）	49（51.04）	34（52.31）	42（52.50）	0.044	0.978
否（n = 116）	47（48.96）	31（47.69）	38（47.50）	0.044	0.978
初潮年龄
> 14岁（n = 120）	42（43.75）	37（56.92）	41（51.25）	2.792	0.248
≤ 14岁（n = 121）	54（56.25）	28（43.08）	39（48.75）	2.792	0.248
痛经史
是（n = 120）	51（53.13）	35（53.85）	34（42.50）	2.556	0.279
否（n = 121）	45（46.88）	30（46.15）	46（57.50）	2.556	0.279

组别	例数	UBE2C	TRIM27
EC组	96	31.42 ± 8.75^ab	51.82 ± 8.93^ab
EAH组	65	27.86 ± 8.21^a	47.16 ± 8.88^a
对照组	80	24.35 ± 8.07	42.39 ± 8.86
F值		15.985	24.573
P值		< 0.001	< 0.001

项目	UBE2C	t值	P值	TRIM27	t值	P值
肿瘤直径
≥ 5 cm（n = 57）	36.01 ± 8.75	6.209	< 0.001	59.83 ± 9.02	10.619	< 0.001
< 5 cm（n = 39）	24.72 ± 8.75	6.209	< 0.001	40.12 ± 8.80	10.619	< 0.001
肿瘤分化程度
低分化（n = 59）	36.52 ± 8.78	7.207	< 0.001	57.62 ± 8.98	8.028	< 0.001
中高分化（n = 37）	23.29 ± 8.71	7.207	< 0.001	42.58 ± 8.86	8.028	< 0.001
淋巴结转移
是（n = 58）	37.58 ± 8.79	8.514	< 0.001	56.71 ± 8.93	6.632	< 0.001
否（n = 38）	22.03 ± 8.69	8.514	< 0.001	44.36 ± 8.91	6.632	< 0.001
FIGO分期
Ⅲ+Ⅳ期（n = 59）	37.23 ± 8.79	8.211	< 0.001	56.27 ± 8.95	6.162	< 0.001
Ⅰ+Ⅱ期（n = 37）	22.16 ± 8.69	8.211	< 0.001	44.73 ± 8.90	6.162	< 0.001
病理类型
子宫内膜样腺癌（n = 46）	32.94 ± 8.76	1.627	0.107	53.03 ± 8.93	1.272	0.207
其他（n = 50）	30.03 ± 8.75	1.627	0.107	50.71 ± 8.93	1.272	0.207
肌层浸润深度
≥ 1/2（n = 55）	38.39 ± 8.76	9.038	< 0.001	59.71 ± 8.95	10.021	< 0.001
< 1/2（n = 41）	22.07 ± 8.74	9.038	< 0.001	41.24 ± 8.91	10.021	< 0.001
宫颈受累
有（n = 55）	33.41 ± 8.77	2.580	0.011	53.72 ± 8.94	2.409	0.018
无（n = 41）	28.75 ± 8.73	2.580	0.011	49.28 ± 8.92	2.409	0.018
雌激素受体表达
阴性（n = 61）	37.96 ± 8.76	9.660	< 0.001	58.59 ± 8.94	9.798	< 0.001
阳性（n = 35）	20.03 ± 8.74	9.660	< 0.001	40.03 ± 8.92	9.798	< 0.001
孕激素受体表达
阴性（n = 60）	38.15 ± 8.77	9.724	< 0.001	59.08 ± 8.96	10.279	< 0.001
阳性（n = 36）	20.21 ± 8.72	9.724	< 0.001	39.72 ± 8.89	10.279	< 0.001

相关指标	UBE2C		TRIM27
相关指标	r值	P值	r值	P值
肿瘤直径	0.455	< 0.001	0.502	< 0.001
肿瘤分化程度	-0.407	< 0.001	-0.408	< 0.001
淋巴结转移	0.435	< 0.001	0.438	< 0.001
FIGO分期	0.424	< 0.001	0.418	< 0.001
肌层浸润深度	0.412	< 0.001	0.409	< 0.001
雌激素受体表达	-0.403	< 0.001	-0.416	< 0.001
孕激素受体表达	-0.409	< 0.001	-0.422	< 0.001

项目	AUC	95%CI	P值	约登指数	截断值（pg/mL）	敏感度（%）	特异度（%）
UBE2C	0.825	0.761 ~ 0.878	< 0.001	0.556	27.01	78.12	77.50
TRIM27	0.825	0.761 ~ 0.878	< 0.001	0.573	44.87	88.54	68.75
联合检测	0.906	0.853 ~ 0.945	< 0.001	0.725		87.50	85.00

Expression level of serum UBE2C and TRIM27 in patients with endometrial cancer and their correlation with pathological parameters

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 6

References 23

Related Articles 14

Recommended Articles

Metrics

Comments

[1]	Yao ZHANG,Yingxin HUO,Wei ZHAO,Rongjie TANG,Qiufang. LIAN. The relationship between blood uric acid levels and non⁃alcoholic fatty liver disease in patients with type H hypertension [J]. The Journal of Practical Medicine, 2024, 40(18): 2561-2565.
[2]	Hongmei LIU,Huahong ZHOU,Xiangjiu CHEN,Guobao HONG,Xiongbin WU,Yanjuan LIANG,Chunting LI,Meidi ZHENG,Yueqin LAI,Fanna. LIU. Association of frailty with anxiety and depression in patients on maintenance hemodialysis [J]. The Journal of Practical Medicine, 2024, 40(18): 2612-2617.
[3]	Tingting YANG,Yidan HUANG,Rongrong YANG,Ying YANG,Jing. ZHANG. Study on the relationship between serum LRG1， LDH with periodontal indexes and periodontal lesions in patients with type 2 diabetes and chronic periodontitis [J]. The Journal of Practical Medicine, 2024, 40(16): 2250-2255.
[4]	Ying LI,Yan LUO,Wenquan LI,Weifeng. LUO. Expression of miR⁃34c and miR⁃29b in peripheral blood of patients with sensorineural deafness and clinical significance [J]. The Journal of Practical Medicine, 2024, 40(15): 2105-2109.
[5]	Yanyun LI,Xueping CHEN,Peipei TIAN,Ting BAI,Qin GUO,Miao. GUO. The correlations of serum Aβ1⁃42， P⁃Tau181， and Hcy levels with sleep disorders in Parkinson′s disease patients [J]. The Journal of Practical Medicine, 2024, 40(11): 1483-1487.
[6]	Wei FANG,Anni FENG,Lanhuan PENG,Yuqin LIAO,Qianyun DENG,Liuqin. CHEN. Application of autoantibody in the diagnosis and treatment of threatened preterm labor [J]. The Journal of Practical Medicine, 2023, 39(24): 3255-3260.
[7]	Peipei LIN,Xiaodong ZHOU,Wei. SONG. Prediction value of tumor volume to uterine volume ratio combined with tumor ADC value in pathological grading of endometrial carcinoma [J]. The Journal of Practical Medicine, 2023, 39(23): 3071-3075.
[8]	HE Jiahao, JIANG Qian, LIU Chunli.. Analysis of the correlation and consistency between thromboelastography and traditional coagulation tests [J]. The Journal of Practical Medicine, 2022, 38(5): 606-610.
[9]	ZHU Xueli, LIN Zhaokun, WANG Liyun.. Correlation between HBV pgRNA expression level andresponsiveness to nucleoside analog therapy in pa⁃ tients with chronic hepatitis B [J]. The Journal of Practical Medicine, 2022, 38(20): 2585-2596.
[10]	ZHOU Fangfang, GUI Tao, HUANG Meihua, GAN Lin, XIONG Lu, ZHOU Wenjuan, CHEN Yan, WANG Zhihui, WAN Guiping. . A study on the TCM syndrome types，constitution，and related risk factors of HR ⁃HPV infection in the uterine cervix [J]. The Journal of Practical Medicine, 2022, 38(2): 234-238.
[11]	WANG Saifeng, SHI Wei, XIE Xianjing.. RBM5 knockout in endometrial cancer cells and its effect [J]. The Journal of Practical Medicine, 2022, 38(10): 1203-1207.
[12]	LI Song, DONG Lili, SUN Li, LI Gang, YUAN Shuang, WANG Xuebo, WANG Ke. Effect of MicroRNA⁃191 on proliferation and invasion of endometrial cancer cells through targeted regula⁃ tion of TET1 [J]. The Journal of Practical Medicine, 2021, 37(8): 1014-1018.
[13]	BO Wei, WANG Xuguang, LI Jiaqi, LIANG Yiling, LI Lei, GOU Jiayu, ZHANG Zhong.. Helicobacter pylori vacA genotypes distribution and relationship with NF ⁃ κB expression in gastric cancer [J]. The Journal of Practical Medicine, 2021, 37(6): 782-786.
[14]	CHU Ye, CHENG Li, JIN Jing, LIU Jianyong.. Correlations between serum γ⁃glutamyltransferase and carotid atherosclerosis in patients with obstructive sleep apnea hypopnea syndrome [J]. The Journal of Practical Medicine, 2021, 37(20): 2651-2655.